SCHEMBL25748387

SCHEMBL25748387

CCCN(C)C(=O)C(=O)c1c[nH]c2c(C)ccc(OCc3ccccc3)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ HTR2A P28223 1/20 0.39
▸ TRPM8 Q7Z2W7 1/20 0.38
▸ APP P05067 1/20 0.37
▸ FFAR4 Q5NUL3 1/20 0.37
▸ PTPN1 P18031 1/20 0.37
▸ LTB4R Q15722 1/20 0.37
▸ LTB4R2 Q9NPC1 1/20 0.37
▸ EDNRA P25101 1/20 0.36
▸ ALOX5 P09917 1/20 0.36
▸ EGFR P00533 2/20 0.36
▸ JAK2 O60674 1/20 0.35
▸ JAK3 P52333 1/20 0.35
▸ RXRA P19793 1/20 0.35
▸ RXRB P28702 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25748377 0.92 SMN1; SMN2 (0.41) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL30483756 0.91 APP (0.42) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL27189618 0.89 MAPT (0.44) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL25748397 0.87 MAPT (0.42) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL25748392 0.85 MAPT (0.41) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL23805264 0.84 HTR2A (0.54) HTR2ATRPM8LTB4RLTB4R2EDNRA
SCHEMBL31077747 0.84 MAPT (0.41) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL25748242 0.82 HTR2A (0.39) SMN1; SMN2HTR2ATRPM8PTPN1LTB4R
SCHEMBL25748376 0.82 MAPT (0.45) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL27189571 0.77 TDP1 (0.40) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250101038-A1 COMPOUNDS Psylo Pty Ltd (AU) 2025-03-27 — — US disclosed
EP-4452937-A1 COMPOUNDS Psylo Pty Ltd (AU) 2024-10-30 — — EP disclosed
CN-118715204-A Compounds of formula (I) 普赛洛私人有限公司 2024-09-27 — — CN disclosed
WO-2023115166-A1 COMPOUNDS Psylo Pty Ltd (AU) 2023-06-29 — — WO disclosed
WO-2023115166-A1 COMPOUNDS Psylo Pty Ltd (AU) 2023-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101038-A1 COMPOUNDS NLN, SLC18A2, PYGB MAPT 139/4885CYP2C9 1232/4885CYP2C19 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback